Senile plaques (ˈsiːnaɪl plæks) refer to the abnormal clumps of protein, primarily amyloid beta, that build up between nerve cells in the brain of people with Alzheimer's disease. This term is a combination of two words. Senile refers to the biological aging process, and plaques refer to the abnormal protein deposits. Pronounced as see-nail placks, this term is commonly used in medical research to study Alzheimer's disease, which affects millions of people worldwide. Early detection of senile plaques can aid in the development of treatments to counteract the effects of Alzheimer's disease.
Senile plaques are abnormal protein deposits that are commonly found in the brains of individuals with Alzheimer's disease or other neurodegenerative disorders. These plaques are one of the hallmarks of neurodegeneration and are formed by the accumulation of beta-amyloid protein fragments in the brain.
The brain contains a protein called amyloid precursor protein (APP) that is normally processed and broken down into smaller fragments. However, in Alzheimer's disease, this processing is altered, leading to the production of beta-amyloid peptides. These peptides have a tendency to clump together and form plaques, which disrupt the normal functioning of brain cells.
Senile plaques typically consist of a central core of beta-amyloid peptides surrounded by various other proteins, including inflammatory molecules. They are commonly found in regions of the brain involved in memory, learning, and cognitive functions.
The presence of senile plaques has been linked to the development and progression of Alzheimer's disease. They are thought to cause damage to nerve cells and contribute to the cognitive decline and memory loss commonly observed in affected individuals. Additionally, the accumulation of these plaques is often accompanied by the formation of neurofibrillary tangles, composed of another protein called tau, which further disrupts neuronal function.
Research efforts aimed at understanding senile plaques and developing therapeutic interventions focus on reducing the production or enhancing the clearance of beta-amyloid peptides, as targeting senile plaque formation may offer potential avenues for treating Alzheimer's and related neurodegenerative diseases.
The term "senile plaques" originates from the field of neuropathology, specifically in reference to Alzheimer's disease.
Etymologically, "senile" is derived from the Latin word "senilis", which means "pertaining to old age". The term was originally used to classify age-related conditions or characteristics.
"Plaques" in this context refers to the abnormal protein deposits that accumulate in the brains of individuals with Alzheimer's disease. These protein deposits are mainly composed of a substance called amyloid-beta.
Therefore, "senile plaques" essentially describes the characteristic protein deposits found in the brains of elderly individuals affected by Alzheimer's disease.